Los Angeles, CA – In a significant development that offers a beacon of hope for patients grappling with one of the most aggressive and devastating forms of brain cancer, researchers at Keck Medicine of USC have potentially uncovered an effective combination therapy for glioblastoma. This formidable brain tumor diagnosis is notorious for its resistance to conventional treatments, leaving patients with a grim prognosis; the National Brain Tumor Society reports an average survival of just eight months. However, a new study suggests that a novel triple-threat approach, combining Tumor Treating Fields (TTFields) therapy with immunotherapy and chemotherapy, may fundamentally redefine the therapeutic landscape for this challenging disease.
The study, spearheaded by Keck Medicine of USC neuro-oncologists, indicates that integrating TTFields therapy – which employs targeted waves of electric fields to disrupt tumor growth and stimulate the body’s immune system – with the immune checkpoint inhibitor pembrolizumab and the traditional chemotherapy agent temozolomide, can dramatically extend patient survival. This synergistic approach appears to overcome long-standing barriers to effective glioblastoma treatment, particularly by harnessing the body’s own immune defenses in unprecedented ways.
Understanding Glioblastoma: A Formidable Foe
Glioblastoma multiforme (GBM) stands as the most common and deadliest primary malignant brain tumor in adults. Its aggressive nature, characterized by rapid growth and diffuse infiltration into healthy brain tissue, makes complete surgical removal virtually impossible for most patients. Despite advancements in neurosurgery, radiation therapy, and chemotherapy (primarily with temozolomide), the median overall survival has remained stubbornly low for decades. The insidious nature of glioblastoma stems from several factors: its highly resistant cellular architecture, its ability to create an immunosuppressive microenvironment that shields it from the body’s natural defenses, and the formidable blood-brain barrier, which meticulously regulates the passage of substances from the bloodstream into the brain, often impeding therapeutic agents and immune cells alike.
The limited efficacy of conventional treatments has spurred an urgent global quest for innovative therapies. While immunotherapy has revolutionized the treatment of numerous other cancers by unleashing the immune system’s power, it has largely fallen short in glioblastoma when used as a monotherapy. This failure is largely attributed to the tumor’s unique immune-privileged location and its sophisticated mechanisms for evading immune surveillance.
The Evolution of Treatment: From Single Agents to Strategic Combinations
Historically, the battle against glioblastoma has progressed incrementally. Surgery, aiming for maximal safe resection, often serves as the initial step, followed by adjuvant radiation therapy and chemotherapy. Temozolomide, an oral alkylating agent, became the standard-of-care chemotherapy in the early 2000s, offering a modest but significant survival benefit. However, even with this aggressive multimodal approach, recurrence is almost inevitable, and the prognosis remains dire.
The emergence of Tumor Treating Fields therapy, delivered via a portable, non-invasive device, marked a notable shift in the treatment paradigm for glioblastoma. Approved by the FDA in 2015, TTFields work through a distinct biophysical mechanism, disrupting tumor cell division using low-intensity electric fields. When combined with temozolomide, TTFields demonstrated an improvement in overall survival compared to temozolomide alone in clinical trials. Yet, even with TTFields, the overall survival for glioblastoma patients, while improved, still fell far short of what is seen in many other cancer types.
The persistent challenge of glioblastoma’s immunosuppressive environment led researchers to explore strategies that could render these tumors more susceptible to immune attack. Immunotherapy, specifically immune checkpoint inhibitors like pembrolizumab, which block proteins that prevent the immune system from attacking cancer cells, offered a tantalizing prospect. However, as noted, these agents struggled to gain traction in glioblastoma due to the paucity of T cells within the tumor microenvironment and the protective blood-brain barrier.
It was this critical unmet need that prompted Dr. David Tran, MD, PhD, chief of neuro-oncology with Keck Medicine, co-director of the USC Brain Tumor Center, and the corresponding author of the new study, to hypothesize that a synergistic approach might be necessary. His theory centered on the idea that TTFields, beyond their direct anti-proliferative effects, could also serve as an "in situ immunizer," actively reshaping the tumor’s immune landscape to make it more amenable to immunotherapy. This concept formed the bedrock of the innovative combination therapy now showing such promising results.
Supporting Data: Unpacking the Mechanism and Clinical Findings
The core of this groundbreaking discovery lies in the intricate interplay between the three therapeutic modalities.
Tumor Treating Fields (TTFields): A Biophysical Catalyst
TTFields therapy utilizes low-intensity, intermediate-frequency alternating electric fields, generated by an array of ceramic transducers strategically placed on the patient’s scalp. These fields penetrate the brain and exert physical forces on electrically charged components within rapidly dividing tumor cells. By pushing and pulling key structures inside these cells in continually shifting directions, TTFields physically disrupt crucial processes required for cell division, such as microtubule assembly and chromosomal segregation. This leads to mitotic catastrophe and programmed cell death, effectively preventing tumor growth and proliferation. Patients wear the device for approximately 18 hours a day, allowing for continuous therapeutic action.
Crucially, the study highlights that TTFields’ impact extends beyond mere physical disruption. Researchers observed that TTFields actively attract more tumor-fighting T cells – a type of white blood cell critical for adaptive immunity – into and around the glioblastoma. This phenomenon, often referred to as an "in situ immunization," transforms the typically immune-cold glioblastoma microenvironment into a more immune-responsive one.
Immunotherapy (Pembrolizumab): Unleashing and Sustaining the Attack
Pembrolizumab, the immunotherapy agent used in this study, is an immune checkpoint inhibitor (ICI) that targets the PD-1 protein on T cells. By blocking PD-1, pembrolizumab removes the "brakes" on T cells, allowing them to recognize and attack cancer cells more effectively. In the context of glioblastoma, the challenge has always been the scarcity of T cells within the tumor and the suppressive signals from the tumor microenvironment.
However, the study demonstrates a critical synergy: when TTFields draw T cells into the tumor, and subsequently, immunotherapy is administered, these T cells not only become active but also remain active for longer periods. Moreover, the immune response is further enhanced as these initial T cells are replaced by even stronger, more effective tumor-fighting T cells. This suggests that TTFields effectively "primes" the immune system, creating a fertile ground for immunotherapy to exert its full potential, a feat previously elusive in glioblastoma.
Chemotherapy (Temozolomide): The Established Foundation
Temozolomide, while not the primary focus of the immunomodulatory effects, remains a vital component of the standard-of-care for glioblastoma. As an alkylating agent, it damages DNA within cancer cells, leading to their death. Its inclusion in the triple therapy provides a foundational cytotoxic effect, potentially reducing tumor burden and making remaining cells more vulnerable to the combined assault of TTFields and immunotherapy. The study’s findings underscore that while chemotherapy is essential, it achieves its most profound impact when integrated into a strategy that fundamentally alters the tumor’s immune evasion capabilities.
The 2-THE-TOP Phase 2 Clinical Trial: A Glimpse into the Future
The compelling findings emerged from an analysis of data from 2-THE-TOP, a Phase 2 clinical trial. This single-arm, open-label study enrolled 31 newly diagnosed glioblastoma patients who had completed initial chemoradiation therapy. Of these, 26 received the innovative triple combination therapy: TTFields, chemotherapy (temozolomide), and immunotherapy (pembrolizumab).
The treatment regimen was meticulously structured: patients received six to twelve monthly treatments of temozolomide alongside TTFields for up to 24 months, with the duration determined by their response. Immunotherapy was administered every three weeks, starting with the second dose of chemotherapy, also for up to 24 months.
The results were striking:
- Patients receiving the device alongside chemotherapy and immunotherapy lived approximately 10 months longer than historical controls who had used TTFields with chemotherapy alone.
- The triple therapy was associated with a 70% increase in overall survival compared to established benchmarks.
Perhaps one of the most remarkable and counter-intuitive findings concerned a particularly high-risk subgroup: seven of the 26 patients had inoperable tumors due to their challenging locations. These patients typically face the worst prognosis and have the fewest treatment options. Yet, in this study, those with large, inoperable tumors lived approximately 13 months longer than patients who underwent surgical removal of their tumors and showed a significantly stronger immune activation. This suggests that, when it comes to kick-starting the body’s immune response against the cancer, having a larger tumor may provide more targets for the therapy to work against, leading to a more robust anti-tumor immune response.
Official Responses: Expert Perspectives on a Paradigm Shift
Dr. David Tran articulated the profound implications of these findings, likening the therapeutic synergy to a strategic team sport. "By using TTFields with immunotherapy, we prime the body to mount an attack on the cancer, which enables the immunotherapy to have a meaningful effect in ways that it could not before," he explained. "Our findings suggest that TTFields may be the key to unlocking the value of immunotherapy in treating glioblastoma."
Dr. Tran further elaborated on the "team sport" analogy: "Think of it like a team sport – immunotherapy sends players in to attack the tumor (the offense), while TTFields weaken the tumor’s ability to fight back (the defense). And just like in team sports, the best defense is a good offense." This vivid description underscores how TTFields not only directly combat the tumor but also fundamentally alter its defensive posture, making it vulnerable to the immune system’s offensive capabilities.
The finding regarding larger, unresected tumors is particularly significant, as it challenges established paradigms in neuro-oncology. "Further studies are needed to determine the optimal role of surgery in this setting, but these findings may offer hope, particularly for glioblastoma patients who do not have surgery as an option," Dr. Tran noted. This opens new avenues for considering treatment strategies for patients who previously faced extremely limited choices.
Implications: Moving Towards a New Era in Glioblastoma Care
The results of the 2-THE-TOP Phase 2 trial represent a critical step forward in the relentless fight against glioblastoma. If validated in larger, randomized trials, this triple combination therapy could fundamentally alter the standard of care, offering significantly extended survival and improved quality of life for patients. The potential to effectively treat patients with inoperable tumors is especially transformative, as this subgroup has historically faced the most daunting prognoses.
From Promising Results to Global Validation: The Phase 3 Clinical Trial
Recognizing the immense potential of these findings, Keck Medicine of USC is actively participating in a multicenter, randomized Phase 3 clinical trial designed to definitively validate the efficacy and safety of TTFields in combination with immunotherapy and chemotherapy. Dr. Tran, who has dedicated over a decade to researching TTFields, serves as the chair of the steering committee for this pivotal trial, highlighting his deep expertise and commitment to advancing this therapy. Dr. Frances Chow, a neuro-oncologist with USC Norris, is the principal investigator of the Keck Medicine study site.
This ambitious Phase 3 trial, currently open at 28 sites across the United States, Europe, and Israel, aims to enroll over 740 patients through April 2029. Crucially, the trial design includes patients with varying degrees of surgical intervention – those with gross total resection, partial resection, or biopsy-only tumors – to comprehensively assess how surgically removing tumors influences the immune response and the overall effectiveness of the triple therapy. The outcomes of this large-scale trial will be instrumental in establishing this combination therapy as a new standard of care.
A Broader Impact on Cancer Research
Beyond glioblastoma, the principles uncovered in this study could have wider implications for other cancers that have historically resisted immunotherapy due to their "immune-cold" microenvironments. The concept of using a physical modality like TTFields to prime the immune system for a subsequent immunotherapy attack offers a novel blueprint for overcoming immune evasion in various tumor types. This research underscores the growing understanding that multi-modal approaches, leveraging diverse mechanisms of action, are often the most effective strategies against complex diseases like cancer.
The relentless pursuit of breakthroughs by institutions like Keck Medicine of USC, combined with collaborative efforts across global research networks, offers tangible hope that glioblastoma, once considered an almost insurmountable challenge, may eventually become a more manageable disease, potentially even transitioning towards a chronic condition for many patients. This study is not just about extending lives; it’s about fundamentally rethinking how we wage war against brain cancer, providing a clearer path towards a future where glioblastoma patients have more than just hope – they have effective treatments.
Keck School of Medicine of USC authors of this study include Dongjiang Chen, PhD, assistant professor of research neurological surgery; Son Le, PhD, assistant professor of research neurological surgery; Harshit Manektalia, research programmer; Ming Li, PhD, professor of research population and public health sciences; and Adam O’Dell, research lab specialist. Ashley Ghiaseddin, MD, and Maryam Rahman, MD, MS, colleagues from the University of Florida, also contributed to this work.
This study was funded by a grant from Novocure, which manufactures Optune, the TTFields device used in this study. Dr. Tran has received honoraria from Novocure for consultant work. Chen and Tran are inventors of two patent applications related to work reported in this study.
About the Author
